Perinucleolar compartment prevalence has an independent prognostic value for breast cancer

Cancer Research

Volumn 65, Issue 1, 2005, Pages 246-253

  Kamath, Rajesh V ^a   Thor, Ann D ^c   Wang, Chen ^a   Edgerton, Susan M ^c   Slusarczyk, Alicja ^a   Leary, D J ^a   Wang, J ^c   Wiley, E L ^a   Jovanovic, B ^a   Wu, Q ^d   Nayar, R ^a   Kovarik, P ^b   Shi, F ^b   Huang, Sui ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Jr Hospital of Cook County   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CELL COMPARTMENTALIZATION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOLUS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RNA TRANSCRIPTION; SAMPLING; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CELL NUCLEOLUS; CELL NUCLEUS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 19944426204     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
2. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
3. Chung MA, Wazer D, Cady B. Contemporary management of breast cancer. Obstet Gynecol Clin North Am 2002;29:173-88.
4. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-7.
5. Broders AC Sr. Carcinoma of the breast (including carcinoma in situ) and its grades of malignancy and prognosis. W V Med J 1953;49:311-6.
6. Kamath R, Leary DJ, Huang S. Nuclear components and tumor markers, In: Visions of the nucleus-eukaryotic DNA. Stevenson Ranch (CA): American Scientific Publishers; 2004.
7. Nickerson JA. Nuclear dreams: the malignant alteration of nuclear architecture. J Cell Biochem 1998;70:172-80.
8. Leman ES, Getzenberg RH. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002;86:213-23.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
10. Huang S, Deerinck TJ, Ellisman MH, Spector DL. The dynamic organization of the perinucleolar compartment in the cell nucleus. J Cell Biol 1997;137:965-74.
11. Matera AG, Frey MR, Margelot K, Wolin SL. A perinucleolar compartment contains several RNA polymerase III transcripts as well as the polypyrimidine tract-binding protein, hnRNP I. J Cell Biol 1995;129:1181-93.
12. Lee B, Matera AG, Ward DC, Craft J. Association of RNase mitochondrial RNA processing enzyme with ribonuclease P in higher ordered structures in the nucleolus: a possible coordinate role in ribosome biogenesis. Proc Natl Acad Sci U S A 1996;93:11471-6.
13. Wang C, Politz JC, Pederson T, Huang S. RNA polymerase III transcripts and the PTB protein are essential for the integrity of the perinucleolar compartment. Mol Biol Cell 2003;14:2425-35.
14. Huang S, Deerinck TJ, Ellisman MH, Spector DL, The perinucleolar compartment and transcription. J Cell Biol 1998;143:35-47.
15. Timchenko LT, Miller JW, Timchenko NA, et al. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res 1996;24:4407-14.
16. Huttelmaier SIS, Grosheva I, Rudiger M, Singer RH, Jockusch BM. Raverl, a dual compartment protein, is a ligand for PTB/hnRNPI and microfilament attachment proteins. J Cell Biol 2001;155:775-85.
17. Wagner EJ, Garcia-Blanco MA. Polypyrimidine tract binding protein antagonizes exon definition. Mol Cell Biol 2001;21:3281-8.
18. Huang S. Review: perinucleolar structures. J Struct Biol 2000;129:233-40.
19. Zukerberg LR, Yang WI, Gadd M, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
20. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972;34:187-202.
21. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-23.
22. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003;3:573-85.
23. Mokbel K. Towards optimal management of ductal carcinoma in situ of the breast. Eur J Surg Oncol 2003;29:191-7.
24. Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS Suppl 2003;108:1-67.
25. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
26. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001;28:291-304.
27. Mack L, Kerkvliet N, Doig G, O'Malley FP. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 1997;28:974-9.
28. Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol 1997;10:1088-92.
29. Thor A. HER2-a discussion of testing approaches in the USA. Ann Oncol 2001;12 Suppl 1:S101-7.
30. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 2001;93:1120-1.
31. Barker S. Anti-estrogens in the treatment of breast cancer: current status and future directions. Curr Opin Investig Drugs 2003;4:652-7.
32. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
33. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
34. Busch H, Ballal NR, Busch RK, et al. Controls of nucleolar function in cancer cells. Adv Exp Med Biol 1977;92:125-80.